2026 Interim report
Filed with HKEX · Stock code 1167 · · 77 pages · English
2 Corporate Information 4 Financial Highlights 5 Business Highlights 8 Management Discussion and Analysis 31 Supplementary Information 47 Report on Review of Condensed Consolidated Financial Statements 48 Condensed Consolidated Statement of Profit or Loss 49 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 50 Condensed Consolidated Statement of Financial Position 5
Jacobio Pharmaceuticals Group Co., Ltd. on 6ix
Earlier from Jacobio Pharmaceuticals
- Jacobio Announces 2025 Annual Results
- Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
- Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
- Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
- Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
Later from Jacobio Pharmaceuticals
All Jacobio Pharmaceuticals news releasesFollow Jacobio Pharmaceuticals into a list and get an email when it puts out news.
Follow Jacobio Pharmaceuticals